Allogeneic Cell Therapy Market was valued at USD 0.46 Bn. in 2023 and is estimated to grow at a CAGR of 24.5% in the forecasted period. The forecasted revenue hints at a growth of around 2.13 Bn. USD by 2030.Allogeneic Cell Therapy Market Overview
Allogeneic cell therapy involves using cells from a healthy donor rather than the patient's own cells, which distinguishes it from autologous cell therapy. Clinical trials for allogeneic cell-based therapy have significantly increased in recent years. The number of mesenchymal stem cell (MSC) based clinical trials using cellular therapy has doubled over the last five years. The market has huge potential and is highly anticipated, researchers and investors have bid heavily into this market recently. Many pharma companies are launching allogeneic cell therapies to treat patients with chronic diseases. For Example - Adicet Bio, a biotechnology company developing allogeneic gamma delta T cell therapies for cancer and other diseases. The Allogeneic Cell Therapy market is mainly dominated by North America and nearly has 78% of market share. Thus, such a high CAGR OF 24.5% is valid as the Allogeneic cell therapy is one the verge of becoming a huge success in Biotechnology.To know about the Research Methodology :- Request Free Sample Report
Allogeneic Cell Therapy Market Dynamics
Allogeneic Cell Therapy Market Drivers: The key driving factor in Allogeneic Cell Therapy Market has been its use to wider audience. A wider range of patients can be treated with allogeneic cell treatments irrespective of patient's age, health status, or history of previous diseases and also the cells can be used in a larger population because they are not taken from their own body. By doing this, the pool of possible patients is widened and allogeneic cell therapy industry becomes more valuable. The research has been backed by some good results which has been the reason for an exponential growth in the market. Government organisations like FDA and EMA are willing to test and approve Allogeneic cell therapy researches which gives an opportunity for huge investments directly into the R&D. Leading players of Allogeneic Cell Therapy industry are implementing several strategic plans into action to create cutting-edge, allogeneic cell therapies for haematological disease treatment. Covid 19 has had negative impact on Allogeneic Cell Therapy industry, as the research was halted along with investments which created a void in the market. But after Covid – 19, the awareness among people and researchers has changed. This has ushered new directions into the Market. For Example - Lineage Cell Therapeutics obtained USD 5 million from the California Institute for Regenerative Medicine (CIRM) to create a potential SARS-CoV-2 vaccine using VAC, their allogeneic dendritic cell treatment. Also, technological advancements and increase in research have helped the Allogeneic cell therapy market grow. Challenges in Allogeneic Cell Therapy Market Purity of the sample is utmost challenging in Allogeneic Cell Therapy market, as any discrepancy in that can cause many harmful effects. Proper screening, testing, and quality control processes are necessary to minimize the risk of transmitting infectious diseases and genetic abnormalities associated with donor cells. Ethical concerns regarding use of donor cells, equitable access, and privacy of donor information all should be properly documented before use, to successfully implement the therapy. So, it becomes a crucial challenge for growth of the key players. Also, upon inserting the new and healthy cell, there are chances that the cells can damage the healthy tissues and not get familiar with the host environment. Thus, the damage can be irreparable and can cause huge problems. Cost is another huge concern especially when a new firm is entering the Allogeneic Cell Therapy demand. As this process is new, its cost is very expensive which act as a challenge for companies. Thus, curtailing this cost and simplifying the complexity of manufacturing and quality control can be a huge task for,market. High manufacturing cost of Allogeneic cell therapy and potential risk involved in its use can be two crucial factors which can hamper the future forecast and deprive the market of its right potential.Allogeneic Cell Therapy Market Trend:
Big companies collaborating with others to gain a better hold over the Allogeneic cell therapy market has been the trend which would further propagate For Example – Adaptiimmune Therapeutics partnered with Roche Group Member, Greentech, to develop and market the Allogeneic cell therapies to treat cancer indications. Recent studies on Allogeneic Cell Therapy have also showed increased focus on tailoring donor cell selection and genetic modifications to specific patient characteristics and optimize treatment according to needs. Technological advancements are going to play a huge role especially considering the future use of market. Technologies like closed-system bioreactors, continuous manufacturing, and next-generation cell culture platforms enable us in increasing accuracy and consistency. Thus, technology will drive the market in future. Treatment of some harmful diseases like multiple sclerosis could also take a revolutionary turn, considering recent advancements in R&D. Allogeneic cell therapy can be combined with other techniques like therapeutic modalities, such as immune checkpoint inhibitors, targeted medicines, or other cell-based therapies. Improved efficiency and lesser side effects hints the future of this coupling techniques. Currently Allogeneic Cell Therapy industry is mainly focused on Oncology and Immune related disorders, but in future with more research, the branches can be used in diverse fields like cardiovascular diseases, neurodegenerative disorders, genetic disorders, and other areas. Allogeneic cell treatments are anticipated to be significantly improved by gene editing technologies like CRISPR-Cas9. Donor cells safety, effectiveness, and tolerance can be increased through precise genetic alterations.Allogeneic Cell Therapy Market Segment Analysis
Based on Therapeutic Area Haematological disorders are mainly concerned with blood and blood forming organs and significant development of Allogeneic cell therapy is surrounded near immunology. Thus, haematological diseases have highest market percentage which is nearly 60% of the total segmentation. Many haematological cases have been cured because of using such therapies and thus contains a larger part of the segment. Dermatological disorders are not so common and do not have much of a market share as compared to haematological disorders.Based on Type Stem cell and Non stem cell are the two types. In 2023, the stem cell therapies market had the greatest share. Diseases that are most frequently treated with allogeneic stem cell treatment include chronic illnesses such blood malignancies, leukaemia, and lymphoma as well as specific blood or autoimmune disorders. Non-Stem therapies are generally involving somatic cells that are isolated from human, administered to patients for cure and then for treatment of diseases
Allogeneic Cell Therapy Market Regional Insights
The creation of high-performance filters, improvements in filter technology, and the growth of the biopharmaceutical sector in emerging economies are all factors that have an impact on the market. Thus, the global economy of the Allogeneic Cell Therapy has started rising steadily. Asia Pacific recorded the highest CAGR amongst the 5 regions. North America emerged as market leader with nearly 80% of the total Allogeneic Cell Therapy market. The market has huge scope in global market due to real life applications and future prospects, which would diversify into many segments of the Allogeneic Cell Therapy industry eventually. North America leads the Allogeneic Cell Therapy market and occupies around nearly 78% of market share in the total market. US leads the way with highest market share amongst the other countries.US big players have contributed thoroughly in this market growth. Adaptimmune Therapeutics, Bluebird Bio, CARsgen Therapeutics are some of the companies with highest contributions. Also, high investments in research and analysis have already increased growth potential of the Allogeneic Cell Therapy industry. Asia Pacific is currently at a steady market share and is forecasted to grow at a rapid rate which is because of increased population, higher demand and well-developed technology. The increased healthcare sector has directly improved the investments and also the internal structure of the pharma and healthcare market. Countries such as China, Japan, South Korea, India, and Singapore are key contributors to the single-use filtration assembly market. China leads the Allogeneic Cell Therapy market and has one of the largest markets in the world Europe has a significant market share in Allogeneic Cell Therapy industry and falls just behind North America. Guidelines and restrictions are provided by the European Medicines Agency (EMA) to guarantee the efficacy, effectiveness, and safety of these treatments. The research and commercialization of allogeneic cell treatments in Europe have been helped by the formation of the Advanced Therapy Medicinal Products (ATMP) regulatory framework. Thus Europe has a huge Allogeneic Cell Therapy market which has the potential to become the leading market player of Allogeneic Cell Industry. The Middle East is an emerging sector with many opportunities and risk. Saudi Arabia, UAE, Qatar have made significant investments to build a sustainable place for biotechnology and research. In Saudi Arabia, the government's Vision 2030 plan aims to diversify the economy and develop the healthcare sector. Other regions of UAE like Dubai, Qatar have also started making healthcare and biotechnology hub, attracting international biotechnology and pharmaceutical companies and research organizations. South America expresses a steady market share and is mainly constricted to bigger countries like Brazil, Argentina. Argentina has focused on innovation, research and development, and quality manufacturing process and ensured that they expand their Allogeneic Cell Therapy market share. Columbia has been investing in healthcare from past decade, which gives it an opportunity to have similar market share as of that of Brazil and Argentina. Other countries like Peru, Chile are also slowly accepting the changes of single use technologiesAllogeneic Cell Therapy: Competitive Analysis
The Allogeneic Cell Therapy market is competitive and has a lot to offer especially in these times, where the Allogeneic Cell Market is blooming. Many new companies have entered the Allogeneic Cell Therapy market like Century Therapeutics who is working on developing allogeneic cell therapies for cancer. They utilize induced pluripotent stem cells to generate targeted immune cells for precision medicine approaches. The rapid progress in technology and scientific understanding has enabled the development of innovative allogeneic cell therapy platforms. Companies are continually improving their manufacturing processes, cell engineering techniques, and product characteristics to gain a competitive edge. ExCellThera is developing allogeneic cell therapies based on their proprietary stem cell expansion technology. Also, government has been initiating and helping such researches by providing the, grants like, Regenerative Medicine Program - NIH supports regenerative medicine research, including allogeneic cell therapy, through various funding mechanisms, grants. Companies in allogeneic cell therapy have been structured according to the work they do like Caribou Biosciences is a biotechnology company specializing in gene editing technologies, including CRISPR-Cas9, while Alaris Therapeutics focuses on allogeneic cell therapies for immune tolerance and autoimmune diseases. Big companies like Allogene Therapeutics focuses on developing off-the-shelf allogeneic CAR-T cell therapies for cancer treatment, Takeda Pharmaceutical Company is a global pharmaceutical company with a focus on oncology and rare diseases. They have a growing presence in the allogeneic cell therapy market through their research and developmentAllogeneic Cell Therapy Market Scope: Inquire before buying
Global Allogeneic Cell Therapy Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2023 Market Size in 2023: US $ 0.46 Bn. Forecast Period 2024 to 2030 CAGR: 24.5% Market Size in 2030: US $ 2.13 Bn. Segments Covered: By Type Stem Cell Therapies Hematopoietic Stem Cell Therapies Mesenchymal Stem Cell Therapies Non-stem Cell Therapies Keratinocytes & Fibroblast-based Therapies Others By Therapeutic Area Haematological disorders Dermatological disorders Others By End User Hospitals Speciality Clinics Research Organisations Global Allogeneic Cell Therapy Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Allogeneic Cell Therapy Market Key Players
1. Allogene Therapeutics - United States 2. Bluebird Bio - United States 3. Mustang Bio - United States 4. NantKwest - United States 5. Nkarta Therapeutics - United States 6. Precision BioSciences - United States 7. Sangamo Therapeutics - United States 8. TCR2 Therapeutics - United States 9. Unum Therapeutics - United States 10. WindMIL Therapeutics - United States 11. Gilead Sciences - United States 12. Iovance Biotherapeutics - United States 13. CRISPR Therapeutics - Switzerland 14. Gamida Cell - Israel 15. Iovance Biotherapeutics - United States 16. Kiadis Pharma - Netherlands 17. MaxCyte - United Kingdom 18. Adaptimmune Therapeutics - United Kingdom 19. Cellectis – France 20. Celyad – Belgium 21. Novartis - Switzerland 22. TC BioPharm - United Kingdom 23. Tessa Therapeutics – Singapore 24. Mesoblast – Australia 25. CARsgen Therapeutics – ChinaFAQs
Q.1) What is the CAGR of Allogeneic Cell Therapy market? Ans: The CAGR for Allogeneic Cell Therapy market is 24.5% Q.2) Which are the leading companies in Allogeneic Cell Therapy market? Ans: Allogene Therapeutics, CRISPR Therapeutics and Takeda Pharmaceuticals Company are some of the leading companies in the Allogeneic Cell Therapy Market Q.3) Which region shows most potential in future? Ans: Asia Pacific is expected to grow exponentially and has the most potential in future due to increasing demand. Q,4) Which is the leading region in Allogeneic Cell Therapy market? Ans: North America is the leading region in the Allogeneic Cell Therapy market. Q.5) What was the forecasted period of this report? Ans: The forecast period for the Allogeneic Cell Therapy market research is 2024 – 2030
1. Allogeneic Cell Therapy Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Allogeneic Cell Therapy Market: Dynamics 2.1. Allogeneic Cell Therapy Market Trends by Region 2.1.1. North America Allogeneic Cell Therapy Market Trends 2.1.2. Europe Allogeneic Cell Therapy Market Trends 2.1.3. Asia Pacific Allogeneic Cell Therapy Market Trends 2.1.4. Middle East and Africa Allogeneic Cell Therapy Market Trends 2.1.5. South America Allogeneic Cell Therapy Market Trends 2.2. Allogeneic Cell Therapy Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Allogeneic Cell Therapy Market Drivers 2.2.1.2. North America Allogeneic Cell Therapy Market Restraints 2.2.1.3. North America Allogeneic Cell Therapy Market Opportunities 2.2.1.4. North America Allogeneic Cell Therapy Market Challenges 2.2.2. Europe 2.2.2.1. Europe Allogeneic Cell Therapy Market Drivers 2.2.2.2. Europe Allogeneic Cell Therapy Market Restraints 2.2.2.3. Europe Allogeneic Cell Therapy Market Opportunities 2.2.2.4. Europe Allogeneic Cell Therapy Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Allogeneic Cell Therapy Market Drivers 2.2.3.2. Asia Pacific Allogeneic Cell Therapy Market Restraints 2.2.3.3. Asia Pacific Allogeneic Cell Therapy Market Opportunities 2.2.3.4. Asia Pacific Allogeneic Cell Therapy Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Allogeneic Cell Therapy Market Drivers 2.2.4.2. Middle East and Africa Allogeneic Cell Therapy Market Restraints 2.2.4.3. Middle East and Africa Allogeneic Cell Therapy Market Opportunities 2.2.4.4. Middle East and Africa Allogeneic Cell Therapy Market Challenges 2.2.5. South America 2.2.5.1. South America Allogeneic Cell Therapy Market Drivers 2.2.5.2. South America Allogeneic Cell Therapy Market Restraints 2.2.5.3. South America Allogeneic Cell Therapy Market Opportunities 2.2.5.4. South America Allogeneic Cell Therapy Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Allogeneic Cell Therapy Industry 2.8. Analysis of Government Schemes and Initiatives For Allogeneic Cell Therapy Industry 2.9. Allogeneic Cell Therapy Market Trade Analysis 2.10. The Global Pandemic Impact on Allogeneic Cell Therapy Market 3. Allogeneic Cell Therapy Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2023-2030 3.1. Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 3.1.1. Stem Cell Therapies 3.1.2. Non-stem Cell Therapies 3.2. Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 3.2.1. Haematological disorders 3.2.2. Dermatological disorders 3.2.3. Others 3.3. Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 3.3.1. Hospitals 3.3.2. Speciality Clinics 3.3.3. Research Organisations 3.4. Allogeneic Cell Therapy Market Size and Forecast, by Region (2023-2030) 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Middle East and Africa 3.4.5. South America 4. North America Allogeneic Cell Therapy Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 4.1. North America Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 4.1.1. Stem Cell Therapies 4.1.2. Non-stem Cell Therapies 4.2. North America Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 4.2.1. Haematological disorders 4.2.2. Dermatological disorders 4.2.3. Others 4.3. North America Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 4.3.1. Hospitals 4.3.2. Speciality Clinics 4.3.3. Research Organisations 4.4. North America Allogeneic Cell Therapy Market Size and Forecast, by Country (2023-2030) 4.4.1. United States 4.4.1.1. United States Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 4.4.1.1.1. Stem Cell Therapies 4.4.1.1.2. Non-stem Cell Therapies 4.4.1.2. United States Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 4.4.1.2.1. Haematological disorders 4.4.1.2.2. Dermatological disorders 4.4.1.2.3. Others 4.4.1.3. United States Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 4.4.1.3.1. Hospitals 4.4.1.3.2. Speciality Clinics 4.4.1.3.3. Research Organisations 4.4.2. Canada 4.4.2.1. Canada Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 4.4.2.1.1. Stem Cell Therapies 4.4.2.1.2. Non-stem Cell Therapies 4.4.2.2. Canada Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 4.4.2.2.1. Haematological disorders 4.4.2.2.2. Dermatological disorders 4.4.2.2.3. Others 4.4.2.3. Canada Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 4.4.2.3.1. Hospitals 4.4.2.3.2. Speciality Clinics 4.4.2.3.3. Research Organisations 4.4.3. Mexico 4.4.3.1. Mexico Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 4.4.3.1.1. Stem Cell Therapies 4.4.3.1.2. Non-stem Cell Therapies 4.4.3.2. Mexico Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 4.4.3.2.1. Haematological disorders 4.4.3.2.2. Dermatological disorders 4.4.3.2.3. Others 4.4.3.3. Mexico Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 4.4.3.3.1. Hospitals 4.4.3.3.2. Speciality Clinics 4.4.3.3.3. Research Organisations 5. Europe Allogeneic Cell Therapy Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 5.1. Europe Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 5.2. Europe Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 5.3. Europe Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 5.4. Europe Allogeneic Cell Therapy Market Size and Forecast, by Country (2023-2030) 5.4.1. United Kingdom 5.4.1.1. United Kingdom Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 5.4.1.2. United Kingdom Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 5.4.1.3. United Kingdom Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 5.4.2. France 5.4.2.1. France Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 5.4.2.2. France Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 5.4.2.3. France Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 5.4.3. Germany 5.4.3.1. Germany Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 5.4.3.2. Germany Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 5.4.3.3. Germany Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 5.4.4. Italy 5.4.4.1. Italy Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 5.4.4.2. Italy Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 5.4.4.3. Italy Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 5.4.5. Spain 5.4.5.1. Spain Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 5.4.5.2. Spain Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 5.4.5.3. Spain Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 5.4.6. Sweden 5.4.6.1. Sweden Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 5.4.6.2. Sweden Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 5.4.6.3. Sweden Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 5.4.7. Austria 5.4.7.1. Austria Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 5.4.7.2. Austria Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 5.4.7.3. Austria Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 5.4.8. Rest of Europe 5.4.8.1. Rest of Europe Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 5.4.8.2. Rest of Europe Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 5.4.8.3. Rest of Europe Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 6. Asia Pacific Allogeneic Cell Therapy Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 6.1. Asia Pacific Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 6.2. Asia Pacific Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.3. Asia Pacific Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 6.4. Asia Pacific Allogeneic Cell Therapy Market Size and Forecast, by Country (2023-2030) 6.4.1. China 6.4.1.1. China Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 6.4.1.2. China Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.4.1.3. China Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 6.4.2. S Korea 6.4.2.1. S Korea Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 6.4.2.2. S Korea Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.4.2.3. S Korea Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 6.4.3. Japan 6.4.3.1. Japan Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 6.4.3.2. Japan Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.4.3.3. Japan Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 6.4.4. India 6.4.4.1. India Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 6.4.4.2. India Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.4.4.3. India Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 6.4.5. Australia 6.4.5.1. Australia Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 6.4.5.2. Australia Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.4.5.3. Australia Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 6.4.6. Indonesia 6.4.6.1. Indonesia Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 6.4.6.2. Indonesia Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.4.6.3. Indonesia Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 6.4.7. Malaysia 6.4.7.1. Malaysia Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 6.4.7.2. Malaysia Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.4.7.3. Malaysia Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 6.4.8. Vietnam 6.4.8.1. Vietnam Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 6.4.8.2. Vietnam Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.4.8.3. Vietnam Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 6.4.9. Taiwan 6.4.9.1. Taiwan Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 6.4.9.2. Taiwan Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.4.9.3. Taiwan Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 6.4.10. Rest of Asia Pacific 6.4.10.1. Rest of Asia Pacific Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 6.4.10.2. Rest of Asia Pacific Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.4.10.3. Rest of Asia Pacific Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 7. Middle East and Africa Allogeneic Cell Therapy Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 7.1. Middle East and Africa Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 7.2. Middle East and Africa Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 7.3. Middle East and Africa Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 7.4. Middle East and Africa Allogeneic Cell Therapy Market Size and Forecast, by Country (2023-2030) 7.4.1. South Africa 7.4.1.1. South Africa Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 7.4.1.2. South Africa Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 7.4.1.3. South Africa Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 7.4.2. GCC 7.4.2.1. GCC Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 7.4.2.2. GCC Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 7.4.2.3. GCC Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 7.4.3. Nigeria 7.4.3.1. Nigeria Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 7.4.3.2. Nigeria Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 7.4.3.3. Nigeria Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 7.4.4. Rest of ME&A 7.4.4.1. Rest of ME&A Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 7.4.4.2. Rest of ME&A Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 7.4.4.3. Rest of ME&A Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 8. South America Allogeneic Cell Therapy Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 8.1. South America Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 8.2. South America Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 8.3. South America Allogeneic Cell Therapy Market Size and Forecast, by End User(2023-2030) 8.4. South America Allogeneic Cell Therapy Market Size and Forecast, by Country (2023-2030) 8.4.1. Brazil 8.4.1.1. Brazil Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 8.4.1.2. Brazil Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 8.4.1.3. Brazil Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 8.4.2. Argentina 8.4.2.1. Argentina Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 8.4.2.2. Argentina Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 8.4.2.3. Argentina Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 8.4.3. Rest Of South America 8.4.3.1. Rest Of South America Allogeneic Cell Therapy Market Size and Forecast, by Type (2023-2030) 8.4.3.2. Rest Of South America Allogeneic Cell Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 8.4.3.3. Rest Of South America Allogeneic Cell Therapy Market Size and Forecast, by End User (2023-2030) 9. Global Allogeneic Cell Therapy Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Allogeneic Cell Therapy Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Allogene Therapeutics - United States 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Bluebird Bio - United States 10.3. Mustang Bio - United States 10.4. NantKwest - United States 10.5. Nkarta Therapeutics - United States 10.6. Precision BioSciences - United States 10.7. Sangamo Therapeutics - United States 10.8. TCR2 Therapeutics - United States 10.9. Unum Therapeutics - United States 10.10. WindMIL Therapeutics - United States 10.11. Gilead Sciences - United States 10.12. Iovance Biotherapeutics - United States 10.13. CRISPR Therapeutics - Switzerland 10.14. Gamida Cell - Israel 10.15. Iovance Biotherapeutics - United States 10.16. Kiadis Pharma - Netherlands 10.17. MaxCyte - United Kingdom 10.18. Adaptimmune Therapeutics - United Kingdom 10.19. Cellectis – France 10.20. Celyad – Belgium 10.21. Novartis - Switzerland 10.22. TC BioPharm - United Kingdom 10.23. Tessa Therapeutics – Singapore 11. Key Findings 12. Industry Recommendations 13. Allogeneic Cell Therapy Market: Research Methodology 14. Terms and Glossary